CANCER-RELATED COGNITIVE IMPAIRMENT: Impact and identification of cancer-related cognitive impairment: Edited by Janet Ellis and Elie Isenberg-GrzedaA review of cognitive screening tools in cancerIsenberg-Grzeda, Eliea,b; Huband, Helenc; Lam, HenrydAuthor Information aDepartment of Psychiatry, University of Toronto bOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario cDalhousie University, Halifax, Nova Scotia dLibrary Services, Sunnybrook Health Sciences Centre, Toronto, Ontario Correspondence to Elie Isenberg-Grzeda, MD, CM, FRCPC, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, TG-230, Toronto, ON, Canada M4N3M5. E-mail: [email protected] Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.supportiveandpalliativecare.com). Current Opinion in Supportive and Palliative Care: March 2017 - Volume 11 - Issue 1 - p 24-31 doi: 10.1097/SPC.0000000000000257 Buy SDC Metrics Abstract Purpose of review Cancer-related cognitive impairment (CRCI) is highly prevalent, and assessment of cognition is crucial in providing optimal cancer care. Neuropsychological assessment (NPA) can be lengthy and expensive. Cognitive screening tools are plenty but validity has not been thoroughly studied for use in cancer patients. Recent findings Our search of the recent literature revealed that the Montreal Cognitive Assessment, Mini–Mental State Examination, and Clock Draw Test were the most frequently studied objective screening tools. The Functional Assessment of Cancer Therapy-Cognitive Function and the Cognitive Symptom Checklist-Work 21 were the most commonly studied subjective measures of perceived cognitive impairment. Evidence supports using the Montreal Cognitive Assessment or the Clock Draw Test over the Mini–Mental State Examination to screen for cognitive impairment within specific patient populations. In addition, adding a subjective measure of cognitive impairment (e.g., Functional Assessment of Cancer Therapy-Cognitive Function) may increase diagnostic sensitivity. Summary These suggest that cognitive screening tools may have a role in screening for CRCI, particularly when full NPA is not feasible. Researchers must continue to conduct high-quality studies to build an evidence to guide best practices in screening for CRCI. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.